Xin Lang Cai Jing·2026-01-15 01:27Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price and significant trading activity, indicating potential investor concerns and market volatility [1] - On January 14, Junshi Biosciences' stock fell by 2.36%, with a trading volume of 678 million yuan, and a net financing outflow of 24.32 million yuan [1] - As of January 14, the total margin balance for Junshi Biosciences was 1.341 billion yuan, with a financing balance of 1.325 billion yuan, representing 4.50% of the circulating market value, which is above the 60th percentile of the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% increase [2] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]